Englebert Financial Advisers LLC Acquires New Shares in Guardant Health, Inc. $GH

Englebert Financial Advisers LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,473 shares of the company’s stock, valued at approximately $976,000. Guardant Health makes up approximately 1.0% of Englebert Financial Advisers LLC’s holdings, making the stock its 24th largest position.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its holdings in Guardant Health by 364.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 12,895 shares of the company’s stock worth $2,300,000 after buying an additional 10,121 shares during the last quarter. Diversify Advisory Services LLC acquired a new position in shares of Guardant Health during the 3rd quarter valued at about $292,000. Fairvoy Private Wealth LLC purchased a new stake in shares of Guardant Health during the 3rd quarter valued at approximately $1,271,000. Jackson Square Capital LLC purchased a new position in Guardant Health in the third quarter worth approximately $451,000. Finally, IFP Advisors Inc increased its position in shares of Guardant Health by 15.7% during the 3rd quarter. IFP Advisors Inc now owns 1,700 shares of the company’s stock worth $303,000 after purchasing an additional 231 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Stephens boosted their target price on Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Piper Sandler reissued an “overweight” rating on shares of Guardant Health in a report on Tuesday, September 15th. BTIG Research restated a “buy” rating and set a $195.00 price objective on shares of Guardant Health in a research report on Wednesday, September 2nd. Bank of America lifted their target price on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Finally, Mizuho increased their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $190.00.

Insider Transactions at Guardant Health

In other news, insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $169.58, for a total value of $10,786,135.90. Following the transaction, the insider directly owned 65,374 shares in the company, valued at $11,086,122.92. This trade represents a 49.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ian Clark sold 14,180 shares of Guardant Health stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares in the company, valued at approximately $472,787. This trade represents a 82.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 178,940 shares of company stock valued at $30,070,911 in the last ninety days. Company insiders own 5.60% of the company’s stock.

Guardant Health Stock Up 3.0%

Guardant Health stock opened at $162.59 on Wednesday. The firm’s 50-day simple moving average is $167.70 and its 200 day simple moving average is $140.50. Guardant Health, Inc. has a 52 week low of $66.59 and a 52 week high of $191.05. The firm has a market capitalization of $21.82 billion, a PE ratio of -46.59 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million for the quarter, compared to analyst estimates of $314.23 million. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. The company’s revenue for the quarter was up 44.3% on a year-over-year basis. On average, research analysts expect that Guardant Health, Inc. will post -3.02 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.